Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

J Cancer Res Clin Oncol · 2023 · PMC10374675 · PMID 37198447

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A trend toward a relation between younger age and p.T790M-positive progression was reported in a published retrospective analysis, but did not reach statistical significance (Wu SG et al. 2020 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.